Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

86 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature.
Hughes DA, Bagust A, Haycox A, Walley T. Hughes DA, et al. Health Econ. 2001 Oct;10(7):601-15. doi: 10.1002/hec.609. Health Econ. 2001. PMID: 11747044 Review.
A review of pharmacoeconomic evaluations, which have applied sensitivity analysis to non-compliance rates, was undertaken to evaluate the impact of non-compliance on the cost-effectiveness of different drug therapies. ...However, it was evident that non-compliance always r
A review of pharmacoeconomic evaluations, which have applied sensitivity analysis to non-compliance rates, was undertaken to evaluate
Coronary artery stents: a rapid systematic review and economic evaluation.
Hill R, Bagust A, Bakhai A, Dickson R, Dündar Y, Haycox A, Mujica Mota R, Reaney A, Roberts D, Williamson P, Walley T. Hill R, et al. Health Technol Assess. 2004 Sep;8(35):iii-iv, 1-242. doi: 10.3310/hta8350. Health Technol Assess. 2004. PMID: 15361315 Review.
In multiple-vessel disease there was no evidence of a difference in mortality (at 1 year) between patients treated surgically and those receiving a stent. ...A similar situation was found for DES versus CABG in multiple-vessel disease. However, DES may not ge …
In multiple-vessel disease there was no evidence of a difference in mortality (at 1 year) between patients treated surgically and tho …
Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T, Pilkington G, Bagust A, Boland A, Oyee J, Tudur-Smith C, Blundell M, Lai M, Martin Saborido C, Greenhalgh J, Dundar Y, Dickson R. Brown T, et al. Health Technol Assess. 2013 Jul;17(31):1-278. doi: 10.3310/hta17310. Health Technol Assess. 2013. PMID: 23886301 Free PMC article. Review.
Direct meta-analysis showed a statistically significant improvement in PFS with gefitinib (Iressa®, AstraZeneca; GEF) compared with DOC + PLAT and PAX + PLAT (HR = 0.49; 95% CI 0.33 to 0.73; and HR = 0.38; 95% CI 0.24 to 0.60, respectively). ...LIMITATIONS: Poor trial qual …
Direct meta-analysis showed a statistically significant improvement in PFS with gefitinib (Iressa®, AstraZeneca; GEF) compared with D …
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.
Fleeman N, Bagust A, Boland A, Dickson R, Dundar Y, Moonan M, Oyee J, Blundell M, Davis H, Armstrong A, Thorp N. Fleeman N, et al. Health Technol Assess. 2011;15(42):1-93, iii-iv. doi: 10.3310/hta15420. Health Technol Assess. 2011. PMID: 22152751 Free PMC article. Review.
REVIEW METHODS: A systematic review of the clinical effectiveness and cost-effectiveness of LAP + AI and TRA + AI was undertaken. ...As a result of differences in the exclusion criteria and because one trial was halted prematurely, comparisons across trials were bel …
REVIEW METHODS: A systematic review of the clinical effectiveness and cost-effectiveness of LAP + AI and TRA + AI was undertaken. ... …
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
Greenhalgh J, Bagust A, Boland A, Martin Saborido C, Oyee J, Blundell M, Dundar Y, Dickson R, Proudlove C, Fisher M. Greenhalgh J, et al. Health Technol Assess. 2011 Sep;15(31):1-178. doi: 10.3310/hta15310. Health Technol Assess. 2011. PMID: 21888837 Free PMC article. Review.
The primary objective in the treatment of all patients with a history of occlusive vascular events and peripheral arterial disease is to prevent the occurrence of new occlusive vascular events. ...REVIEW METHODS: A systematic review of clinical effectiveness and cos …
The primary objective in the treatment of all patients with a history of occlusive vascular events and peripheral arterial disease is …
Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
Saborido CM, Hockenhull J, Bagust A, Boland A, Dickson R, Todd D. Saborido CM, et al. Health Technol Assess. 2010 Jun;14(31):iii-iv, 1-75. doi: 10.3310/hta14310. Health Technol Assess. 2010. PMID: 20569652 Review.
A Markov model structure was chosen because it is assumed that PAF is a condition that causes patients to move between a limited number of relevant health states during their lives. ...The AAD strategy has a very poor probability of being cost-effectiv
A Markov model structure was chosen because it is assumed that PAF is a condition that causes patients to move between a
Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Fleeman N, Bagust A, McLeod C, Greenhalgh J, Boland A, Dundar Y, Dickson R, Tudur Smith C, Davis H, Green J, Pearson M. Fleeman N, et al. Health Technol Assess. 2010 May;14 Suppl 1:47-53. doi: 10.3310/hta14Suppl1/07. Health Technol Assess. 2010. PMID: 20507803 Review.
Therefore economic evidence was derived solely from a de novo economic model developed by the manufacturer. A Markov model was developed to evaluate the cost-effectiveness of pemetrexed/cisplatin compared to gemcitabine/cisplatin, docetaxel/cisplatin and gemcitabine …
Therefore economic evidence was derived solely from a de novo economic model developed by the manufacturer. A Markov model was …
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention.
Greenhalgh J, Bagust A, Boland A, Saborido CM, Fleeman N, McLeod C, Dundar Y, Dickson R, Proudlove C, Kolamunnage-Dona R, Fisher M. Greenhalgh J, et al. Health Technol Assess. 2010 May;14 Suppl 1:31-8. doi: 10.3310/hta14Suppl1/05. Health Technol Assess. 2010. PMID: 20507801 Review.
The submitted clinical evidence was based on a phase III double-blind, double-dummy randomised controlled trial which compared the use of prasugrel with clopidogrel. ...Secondary outcomes included the primary end point at 30 days and 90 days; a composite end point o …
The submitted clinical evidence was based on a phase III double-blind, double-dummy randomised controlled trial which compared the us …
The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation.
Fleeman N, McLeod C, Bagust A, Beale S, Boland A, Dundar Y, Jorgensen A, Payne K, Pirmohamed M, Pushpakom S, Walley T, de Warren-Penny P, Dickson R. Fleeman N, et al. Health Technol Assess. 2010 Jan;14(3):1-157, iii. doi: 10.3310/hta14030. Health Technol Assess. 2010. PMID: 20031087 Review.
REVIEW METHODS: A systematic review of analytical validity, clinical validity and clinical utility of CYP testing was undertaken. ...A review of economic evaluations of CYP testing in psychiatry and a review of economic models related to schizophrenia were al …
REVIEW METHODS: A systematic review of analytical validity, clinical validity and clinical utility of CYP testing was undertaken. ... …
Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Greenhalgh J, Bagust A, Boland A, Fleeman N, McLeod C, Dundar Y, Proudlove C, Shaw R. Greenhalgh J, et al. Health Technol Assess. 2009 Oct;13 Suppl 3:49-54. doi: 10.3310/hta13suppl3/08. Health Technol Assess. 2009. PMID: 19846029 Review.
The ERG also questioned the appropriateness of economic modelling in this STA as evidence is available only from a single RCT. In conclusion, the ERG considers that patients with metastatic SCCHN were not shown to receive a significant survival benefit from cetuxima …
The ERG also questioned the appropriateness of economic modelling in this STA as evidence is available only from a single RCT. In con …
86 results
Jump to page
Feedback